Johnson & Johnson (NYSE:JNJ) Holdings Boosted by Oxford Asset Management LLP

Oxford Asset Management LLP grew its stake in Johnson & Johnson (NYSE:JNJ - Free Report) by 257.8% during the fourth quarter, according to its most recent 13F filing with the SEC. The firm owned 12,219 shares of the company's stock after acquiring an additional 8,804 shares during the period. Johnson & Johnson comprises 0.9% of Oxford Asset Management LLP's investment portfolio, making the stock its 10th biggest holding. Oxford Asset Management LLP's holdings in Johnson & Johnson were worth $1,767,000 as of its most recent filing with the SEC.

A number of other hedge funds have also recently made changes to their positions in the stock. Coldstream Capital Management Inc. increased its position in Johnson & Johnson by 0.5% during the fourth quarter. Coldstream Capital Management Inc. now owns 48,436 shares of the company's stock worth $7,005,000 after buying an additional 252 shares during the period. Capital Analysts LLC raised its stake in Johnson & Johnson by 1.4% during the 4th quarter. Capital Analysts LLC now owns 43,027 shares of the company's stock valued at $6,223,000 after acquiring an additional 580 shares during the last quarter. Cheviot Value Management LLC grew its stake in shares of Johnson & Johnson by 9.8% in the 4th quarter. Cheviot Value Management LLC now owns 155,318 shares of the company's stock valued at $22,462,000 after purchasing an additional 13,823 shares during the last quarter. Voya Financial Advisors Inc. increased its holdings in shares of Johnson & Johnson by 6.0% in the fourth quarter. Voya Financial Advisors Inc. now owns 4,998 shares of the company's stock valued at $716,000 after purchasing an additional 282 shares during the period. Finally, Topsail Wealth Management LLC acquired a new stake in shares of Johnson & Johnson during the fourth quarter worth $369,000. Hedge funds and other institutional investors own 69.55% of the company's stock.

Johnson & Johnson Stock Performance

Shares of NYSE JNJ traded down $0.21 during trading on Wednesday, reaching $155.70. The stock had a trading volume of 2,376,699 shares, compared to its average volume of 9,617,642. The stock has a market cap of $374.63 billion, a PE ratio of 23.41, a P/E/G ratio of 2.56 and a beta of 0.49. The firm's 50 day moving average price is $159.36 and its two-hundred day moving average price is $154.77. Johnson & Johnson has a one year low of $140.68 and a one year high of $169.99. The company has a debt-to-equity ratio of 0.43, a quick ratio of 0.86 and a current ratio of 1.11.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last issued its earnings results on Tuesday, April 15th. The company reported $2.77 earnings per share for the quarter, topping the consensus estimate of $2.59 by $0.18. The firm had revenue of $21.89 billion for the quarter, compared to analyst estimates of $21.65 billion. Johnson & Johnson had a return on equity of 34.24% and a net margin of 18.20%. On average, research analysts forecast that Johnson & Johnson will post 10.58 earnings per share for the current fiscal year.

Johnson & Johnson Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, June 10th. Stockholders of record on Tuesday, May 27th will be issued a dividend of $1.30 per share. This represents a $5.20 dividend on an annualized basis and a dividend yield of 3.34%. The ex-dividend date is Tuesday, May 27th. This is a boost from Johnson & Johnson's previous quarterly dividend of $1.24. Johnson & Johnson's payout ratio is 57.84%.

Analysts Set New Price Targets

JNJ has been the topic of several recent analyst reports. Benchmark upgraded shares of Johnson & Johnson to a "strong-buy" rating in a research report on Thursday, April 24th. The Goldman Sachs Group raised Johnson & Johnson from a "neutral" rating to a "buy" rating and raised their price objective for the company from $157.00 to $172.00 in a research note on Wednesday, April 9th. Guggenheim reissued a "neutral" rating on shares of Johnson & Johnson in a report on Wednesday, April 2nd. Royal Bank of Canada reaffirmed an "outperform" rating and set a $181.00 price target on shares of Johnson & Johnson in a research note on Wednesday, April 16th. Finally, Stifel Nicolaus reduced their target price on shares of Johnson & Johnson from $170.00 to $155.00 and set a "hold" rating on the stock in a report on Thursday, January 23rd. Nine investment analysts have rated the stock with a hold rating, eight have given a buy rating and three have given a strong buy rating to the company's stock. According to data from MarketBeat.com, Johnson & Johnson currently has a consensus rating of "Moderate Buy" and a consensus price target of $171.82.

Insider Buying and Selling

In related news, EVP Timothy Schmid sold 403 shares of the firm's stock in a transaction that occurred on Tuesday, February 18th. The shares were sold at an average price of $156.15, for a total transaction of $62,928.45. Following the transaction, the executive vice president now owns 15,098 shares in the company, valued at $2,357,552.70. This trade represents a 2.60 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, VP Robert J. Decker sold 6,999 shares of the company's stock in a transaction that occurred on Tuesday, February 25th. The stock was sold at an average price of $165.88, for a total value of $1,160,994.12. Following the completion of the sale, the vice president now owns 21,001 shares of the company's stock, valued at $3,483,645.88. This trade represents a 25.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Corporate insiders own 0.16% of the company's stock.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.